Literature DB >> 16131417

Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: etiology and management.

Dag Aarsland1, Sally Sharp, Clive Ballard.   

Abstract

Psychiatric and behavioral symptoms are common in all types of dementia and have important consequences for patients, caregivers, and society. This paper reviews recent studies of the etiology and management of these symptoms. Genetic and neurochemical studies indicate that cholinergic, serotonergic, and dopaminergic systems may influence the risk of psychiatric symptoms in patients with dementia. There is still no consensus regarding the management of such symptoms. Controlled studies of psychosocial interventions, usually performed in the nursing home setting, report encouraging results. Atypical antipsychotics may be effective in some cases but have a high risk of adverse events. There is emerging evidence that cholinesterase inhibitors may reduce and prevent such symptoms. More studies are needed to clarify the role of cholinergic and other psychotropic agents as well as nonpharmacologic interventions for psychiatric and behavioral symptoms in patients with dementia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16131417     DOI: 10.1007/s11910-005-0058-4

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  76 in total

1.  Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis.

Authors:  R A Sweet; R L Hamilton; M T Healy; S R Wisniewski; R Henteleff; B G Pollock; D A Lewis; S T DeKosky
Journal:  Arch Neurol       Date:  2001-03

2.  Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data.

Authors:  Henry A Nasrallah; Thantween White; Amelia T Nasrallah
Journal:  Am J Geriatr Psychiatry       Date:  2004 Jul-Aug       Impact factor: 4.105

3.  Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.

Authors:  Clive Ballard; Marisa Margallo-Lana; Edmund Juszczak; Simon Douglas; Alan Swann; Alan Thomas; John O'Brien; Anna Everratt; Stuart Sadler; Clare Maddison; Lesley Lee; Carol Bannister; Ruth Elvish; Robin Jacoby
Journal:  BMJ       Date:  2005-02-18

4.  One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer's disease. The REAL.FR Study.

Authors:  M Benoit; P H Robert; P Staccini; P Brocker; O Guerin; L Lechowski; B Vellas
Journal:  J Nutr Health Aging       Date:  2005       Impact factor: 4.075

5.  Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial.

Authors:  J B Deakin; S Rahman; P J Nestor; J R Hodges; B J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2003-12-10       Impact factor: 4.530

6.  Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa.

Authors:  Clive G Ballard; John T O'Brien; Katharina Reichelt; Elaine K Perry
Journal:  J Clin Psychiatry       Date:  2002-07       Impact factor: 4.384

7.  Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease.

Authors:  Frédéric Assal; Maricela Alarcón; Esther C Solomon; Donna Masterman; Daniel H Geschwind; Jeffrey L Cummings
Journal:  Arch Neurol       Date:  2004-08

8.  The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.

Authors:  C Holmes; D Wilkinson; C Dean; S Vethanayagam; S Olivieri; A Langley; N D Pandita-Gunawardena; F Hogg; C Clare; J Damms
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

9.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

10.  Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine.

Authors:  E R Peskind; D Wingerson; S Murray; M Pascualy; D J Dobie; P Le Corre; R Le Verge; R C Veith; M A Raskind
Journal:  Arch Gen Psychiatry       Date:  1995-09
View more
  3 in total

1.  Treatment of Vascular Cognitive Impairment.

Authors:  Aaron Ritter; Jagan A Pillai
Journal:  Curr Treat Options Neurol       Date:  2015-08       Impact factor: 3.598

2.  Relationship between Dementia Severity and Behavioral and Psychological Symptoms of Dementia in Dementia with Lewy Bodies and Alzheimer's Disease Patients.

Authors:  Mamoru Hashimoto; Yusuke Yatabe; Tomohisa Ishikawa; Ryuji Fukuhara; Keiichiro Kaneda; Kazuki Honda; Seiji Yuki; Yusuke Ogawa; Toru Imamura; Hiroaki Kazui; Naoto Kamimura; Syunichiro Shinagawa; Katsuyoshi Mizukami; Etsuro Mori; Manabu Ikeda
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2015-06-06

Review 3.  Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinson's Disease.

Authors:  Dominika Fricova; Jana Harsanyiova; Alzbeta Kralova Trancikova
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.